Drugs / GLPG3121
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04856358 | Apr → Nov 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03899909 | Mar → Jun 2019 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG3121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03899909 ↗ |
| Route | Oral | “GLPG3121 oral suspension, single ascending doses” NCT03899909 ↗ |